Suzhou Youqin Medical Laboratory

Suzhou Youqin Medical Laboratory is a specialized facility focused on hematological diagnostics, providing high-quality medical testing, research services, and innovative diagnostic technologies to healthcare institutions. Founded in 2017 in Suzhou, China, Suzhou Youqin Medical Laboratory specializes in hematological disease diagnosis. The company has engaged in one funding round, with the most recent deal occurring on May 6, 2025, when Adicon Clinical Laboratories, Inc. announced the acquisition of the laboratory for CNY 50 million.

The firm was established by individuals with an extensive background in medical research and diagnostics. Suzhou Youqin Medical Laboratory specializes in the diagnosis of hematological diseases, offering a comprehensive suite of services that includes medical testing, reagent production, and research services. Their core product offerings encompass a well-developed MICM precision diagnostic platform for hematological tumors and integrated diagnostic services for bleeding and thrombotic disorders. Additionally, the laboratory provides extensive monitoring systems for hematopoietic stem cell transplantation.

The company has successfully launched over 500 testing projects that focus on conditions such as leukemia, multiple myeloma, and lymphoma, catering to hospitals and healthcare providers primarily in mainland China. Their advanced diagnostic platforms utilize state-of-the-art equipment like flow cytometers, PCR amplifiers, and high-throughput sequencing systems, which enable precise and efficient testing tailored to clinicians' needs. The revenue structure of Suzhou Youqin Medical Laboratory is primarily derived from service fees associated with their diagnostic testing and research projects. Transactions typically occur on a B2B basis, with healthcare institutions and laboratories as the main clients.

These clients engage Yuande Youqin for specialized services, including tailored diagnostic consultations and training for advanced testing platforms, reflecting the company's commitment to integrating expertise with technology. Pricing structures are established based on the complexity and scope of the services provided, which may include both one-time fees for specific tests and ongoing partnerships for routine testing and consultation services. This strategic approach allows the company to maintain a steady revenue stream while fostering long-term relationships with their client base. In May 2025, Adicon Clinical Laboratories, Inc.

announced the full acquisition of Suzhou Youqin Medical Laboratory for CNY 50 million. Following this acquisition, the company plans to enhance its diagnostic offerings with the introduction of new products aimed at expanding its hematological testing capabilities by late 2025. Additionally, Suzhou Youqin Medical Laboratory is targeting growth in international markets, specifically in Southeast Asia and Europe, planning to establish operational bases by 2026. The recent funding will be utilized to support these product developments and expansion efforts, positioning the company for increased market share in the global healthcare diagnostics sector.